Artiva Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Artiva Biotherapeutics Common
ARTV Stock   4.14  0.04  0.96%   
Artiva Biotherapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Artiva Biotherapeutics' valuation are provided below:
Market Capitalization
82.8 M
Enterprise Value Revenue
7.5448
Earnings Share
(6.15)
Quarterly Revenue Growth
(1.00)
There are over one hundred nineteen available fundamental signals for Artiva Biotherapeutics Common, which can be analyzed over time and compared to other ratios. All traders should should validate Artiva Biotherapeutics' prevailing fundamental trends against the trends from 2010 to 2026 to make sure the company is sustainable.

Artiva Biotherapeutics Total Revenue

274,218

Check Artiva Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Artiva Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.9 M, as well as many indicators such as Price To Sales Ratio of 925, Dividend Yield of 0.0 or PTB Ratio of 1.24. Artiva financial statements analysis is a perfect complement when working with Artiva Biotherapeutics Valuation or Volatility modules.
  
Build AI portfolio with Artiva Stock
Check out the analysis of Artiva Biotherapeutics Correlation against competitors.

Artiva Biotherapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets253.1 M241 M70 M
Slightly volatile
Short and Long Term Debt Total11.4 M16.5 M9.5 M
Slightly volatile
Other Current Liabilities7.2 M8.5 M3.5 M
Slightly volatile
Total Current Liabilities14 M14.1 M6.6 M
Slightly volatile
Property Plant And Equipment Net15 M23.5 M8.4 M
Slightly volatile
Accounts Payable891.2 K1 M641.5 K
Slightly volatile
Cash70.5 M46.3 M30.5 M
Slightly volatile
Non Current Assets Total16.2 M24.1 M9.1 M
Slightly volatile
Non Currrent Assets Other880.9 K472.5 K667.8 K
Slightly volatile
Long Term Debt4.5 M5.1 M5.5 M
Slightly volatile
Cash And Short Term Investments223.9 M213.2 M59.2 M
Slightly volatile
Liabilities And Stockholders Equity253.1 M241 M70 M
Slightly volatile
Non Current Liabilities Total11.7 M12.3 M53 M
Slightly volatile
Other Current Assets3.7 M3.5 M908.1 K
Slightly volatile
Other Stockholder Equity523.4 M498.5 M87.8 M
Slightly volatile
Total Liabilities25.1 M26.4 M59.6 M
Slightly volatile
Total Current Assets227.8 M216.9 M60.3 M
Slightly volatile
Short Term Debt2.2 M4.3 M1.2 M
Slightly volatile
Common Stock Shares Outstanding22.1 M28 M19.2 M
Slightly volatile
Capital Lease Obligations12 M16.5 M6.1 M
Slightly volatile
Property Plant And Equipment Gross19.9 M30.3 M9.7 M
Slightly volatile
Non Current Liabilities Other75.7 K65.7 K113.2 K
Slightly volatile
Net Working Capital107 M202.8 M58.8 M
Slightly volatile
Current Deferred Revenue10 M12.5 M8.4 M
Slightly volatile
Other Assets4 K4.5 K4.9 K
Slightly volatile
Common Stock2.4 K2.7 K2.9 K
Slightly volatile

Artiva Biotherapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.9 M2.8 M743.4 K
Slightly volatile
Selling General Administrative15.2 M19.8 M8.7 M
Slightly volatile
Other Operating Expenses59.4 M77.7 M34.7 M
Slightly volatile
Research Development44.2 M57.9 M26 M
Slightly volatile
Total Operating Expenses59.4 M77.7 M34.7 M
Slightly volatile
Reconciled Depreciation2.9 M2.8 M743.4 K
Slightly volatile
Gross Profit274.2 K288.6 K3.7 M
Pretty Stable

Artiva Biotherapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.5 M8 M2.5 M
Slightly volatile
Begin Period Cash Flow75.9 M61.8 M29.5 M
Slightly volatile
Depreciation2.9 M2.8 M743.4 K
Slightly volatile
Capital Expenditures701.4 K738.3 K969.8 K
Slightly volatile
End Period Cash Flow61.4 M36.4 M43.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio925881241
Slightly volatile
Days Sales Outstanding20119199.1728
Slightly volatile
Stock Based Compensation To Revenue26.2825.036.2636
Slightly volatile
Capex To Depreciation0.290.33.381
Slightly volatile
EV To Sales827788167
Slightly volatile
Sales General And Administrative To Revenue64.7861.6916.2795
Slightly volatile
Research And Ddevelopement To Revenue18918049.1221
Slightly volatile
Capex To Revenue2.422.31.1168
Slightly volatile
Cash Per Share4.386.853.1204
Slightly volatile
Income Quality0.690.760.7824
Pretty Stable
Net Debt To EBITDA0.440.461.2277
Slightly volatile
Current Ratio14.5513.865.1872
Slightly volatile
Receivables Turnover1.471.554.9715
Pretty Stable
Capex Per Share0.02250.02370.0498
Slightly volatile
Revenue Per Share0.00880.00930.1832
Pretty Stable
Interest Debt Per Share0.420.530.2893
Slightly volatile
Debt To Assets0.07480.07880.9866
Slightly volatile
Operating Cycle20119199.1728
Slightly volatile
Ebt Per Ebit1.121.01.0026
Pretty Stable
Long Term Debt To Capitalization2.683.023.2925
Slightly volatile
Quick Ratio14.5513.865.1872
Slightly volatile
Net Income Per E B T0.80.90.9834
Slightly volatile
Cash Ratio3.522.962.9861
Slightly volatile
Cash Conversion Cycle20119199.1728
Slightly volatile
Days Of Sales Outstanding20119199.1728
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.181.161.0522
Slightly volatile
Fixed Asset Turnover0.01340.01410.4393
Slightly volatile
Debt Ratio0.07480.07880.9866
Slightly volatile
Price Sales Ratio925881241
Slightly volatile
Asset Turnover0.0010.00110.0294
Pretty Stable

Artiva Biotherapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap196.5 M221 M241.2 M
Slightly volatile
Enterprise Value175.8 M197.7 M215.8 M
Slightly volatile

Artiva Fundamental Market Drivers

About Artiva Biotherapeutics Financial Statements

Artiva Biotherapeutics investors use historical fundamental indicators, such as Artiva Biotherapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Artiva Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue12.5 M10 M
Total Revenue288.6 K274.2 K
Stock Based Compensation To Revenue 25.03  26.28 
Sales General And Administrative To Revenue 61.69  64.78 
Research And Ddevelopement To Revenue 180.46  189.48 
Capex To Revenue 2.30  2.42 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(308.26)(292.85)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Artiva Stock Analysis

When running Artiva Biotherapeutics' price analysis, check to measure Artiva Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics is operating at the current time. Most of Artiva Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics' price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY